These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12675529)

  • 21. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced therapeutic agent delivery through magnetic resonance imaging-monitored focused ultrasound blood-brain barrier disruption for brain tumor treatment: an overview of the current preclinical status.
    Liu HL; Yang HW; Hua MY; Wei KC
    Neurosurg Focus; 2012 Jan; 32(1):E4. PubMed ID: 22208897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug delivery strategies for the treatment of malignant gliomas.
    Allhenn D; Boushehri MA; Lamprecht A
    Int J Pharm; 2012 Oct; 436(1-2):299-310. PubMed ID: 22721856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
    Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
    J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation of drug delivery from drug effect: problems of optimizing drug delivery parameters.
    Ali MJ; Navalitloha Y; Vavra MW; Kang EW; Itskovich AC; Molnar P; Levy RM; Groothuis DR
    Neuro Oncol; 2006 Apr; 8(2):109-18. PubMed ID: 16533759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell surface receptors in malignant glioma.
    Li YM; Hall WA
    Neurosurgery; 2011 Oct; 69(4):980-94; discussion 994. PubMed ID: 21522029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).
    Chamberlain MC
    Neuro Oncol; 2011 May; 13(5):558-9; author reply 561-2. PubMed ID: 21558078
    [No Abstract]   [Full Text] [Related]  

  • 28. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas.
    Weyerbrock A; Walbridge S; Pluta RM; Saavedra JE; Keefer LK; Oldfield EH
    J Neurosurg; 2003 Oct; 99(4):728-37. PubMed ID: 14567609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
    Chenevert TL; Stegman LD; Taylor JM; Robertson PL; Greenberg HS; Rehemtulla A; Ross BD
    J Natl Cancer Inst; 2000 Dec; 92(24):2029-36. PubMed ID: 11121466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tackling gliomas with nanoformulated antineoplastic drugs: suitability of hyaluronic acid nanoparticles.
    Ganau M
    Clin Transl Oncol; 2014 Feb; 16(2):220-3. PubMed ID: 24072561
    [No Abstract]   [Full Text] [Related]  

  • 32. Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.
    Folaron M; Seshadri M
    Mol Imaging Biol; 2016 Dec; 18(6):860-869. PubMed ID: 27160251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy.
    Sijens PE; Heesters MA; Enting RH; van der Graaf WT; Potze JH; Irwan R; Meiners LC; Oudkerk M
    Cancer Invest; 2007 Dec; 25(8):706-10. PubMed ID: 18058466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective change of blood flow in experimental brain tumor with induced hypertension.
    Matsuura H; Ikeda Y; Imaya H; Nakazawa S
    Surg Neurol; 1987 May; 27(5):433-6. PubMed ID: 3563857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment.
    Fan CH; Ting CY; Liu HL; Huang CY; Hsieh HY; Yen TC; Wei KC; Yeh CK
    Biomaterials; 2013 Mar; 34(8):2142-55. PubMed ID: 23246066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.
    Drapeau A; Fortin D
    Curr Cancer Drug Targets; 2015; 15(9):752-68. PubMed ID: 26077730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.
    Haryu S; Saito R; Jia W; Shoji T; Mano Y; Sato A; Kanamori M; Sonoda Y; Sampetrean O; Saya H; Tominaga T
    J Neurooncol; 2018 Jan; 136(1):23-31. PubMed ID: 28929335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia in Gliomas: Opening Therapeutical Opportunities Using a Mathematical-Based Approach.
    Martı Nez-González A; Calvo GF; Ayuso JM; Ochoa I; Fernández LJ; Pérez-García VM
    Adv Exp Med Biol; 2016; 936():11-29. PubMed ID: 27739041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats.
    Erdlenbruch B; Jendrossek V; Kugler W; Eibl H; Lakomek M
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):299-304. PubMed ID: 12357304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma.
    Zhang F; Xu CL; Liu CM
    Drug Des Devel Ther; 2015; 9():2089-100. PubMed ID: 25926719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.